Summary#
This bill would let the Department of Health and Human Services (HHS) do research and give grants to states to boost early detection of and intervention for uterine fibroids. The main change is a new federal grant and research program focused on screening, patient help, public education, and some clinical research. The broad goal is to find and treat uterine fibroids earlier and to study related gaps in care.
- Main change: HHS may fund research and award grants to states for programs that increase early detection and intervention for uterine fibroids and run public awareness campaigns.
- Screening and payment: Grants may pay for screening procedures, including advanced gynecological imaging.
- Patient support: Grants may pay for patient navigation services (help with appointments, referrals, and understanding care).
- Research focus: HHS may fund research and clinical trials on disparities in pain control during fibroid surgery and on Asherman’s Syndrome and other intrauterine conditions. (Asherman’s Syndrome is scarring inside the uterus that can affect fertility and bleeding.)
- Reporting: HHS must report to Congress and publish findings on grant programs and related research starting 2 years after the first grants and every 2 years after that.
What it means for you#
- People with uteruses (patients): This could mean more public information about fibroids, easier access to screening, and help navigating care in states that get grants. It could also support research into better pain control and certain intrauterine conditions.
- States: States could apply for and receive federal grants to set up screening programs, pay for imaging, run awareness campaigns, hire patient navigators, and put into place evidence-based strategies from HHS.
- Health care providers and clinics: Providers in funded states may see new screening programs, more referrals, additional imaging demand, and opportunities to take part in research or clinical trials.
- Researchers and hospitals: The bill authorizes funding for clinical research and trials on pain management disparities and intrauterine conditions.
- General public / taxpayers: The bill creates new federal activities at HHS, but the bill text does not set specific funding amounts.
Expenses#
No publicly available information.
- The bill authorizes HHS to run programs and award grants, but it does not specify any dollar amounts or how grants would be funded.
- Because no funding level is stated, the cost to the federal government is not included in the bill text provided.
- State and local costs could arise if states choose to add programs beyond what grant funds cover, but the bill does not detail those possibilities.
Proponents' View#
- The bill appears intended to improve early detection and treatment of uterine fibroids, which could lead to better health outcomes.
- It could increase access to screening and to services that help patients get timely care, such as patient navigation.
- Funding research and clinical trials may identify better approaches to pain control in fibroid surgery and improve understanding of intrauterine conditions like Asherman’s Syndrome.
- Regular public reports to Congress and posting results on HHS’s website could increase transparency about what programs work.
Opponents' View#
- One concern is that the bill does not set or authorize a specific funding amount, so it is unclear whether grants will be large enough to have a wide impact.
- The bill gives HHS permission to award grants but does not require that grants be awarded; the reach of the program will depend on future budget choices.
- The bill does not explain how states will be chosen for grants, how success will be measured, or how long grants would last. These implementation details are unclear.
- It is not specified how patient privacy or data protections will be handled in research and reporting.
- Without specified funding or program rules, the quality and equity of services could vary between states.